Organon & Co. (OGN) Securities Class Action Lawsuit Update [June 19, 2025]

Introduction  to Organon & Co. (OGN) Securities Lawsuit

A securities fraud class action lawsuit has been filed against Organon & Co. (“Organon”) (NYSE: OGN) on behalf of investors who purchased the company’s common stock between October 31, 2024, and April 30, 2025 (the “Class Period”). Plaintiffs claim Organon and certain senior executives violated federal securities laws, such as the Securities Exchange Act, by making false or misleading statements about the company’s financial allocation priorities.  The Complaint claims Organon repeatedly affirmed its regular quarterly dividend was the top priority; however, the Company’s debt reduction plans called for a massive dividend cut.  When Organon investors learned this news, Organon stock crashed 27%. 

Organon & Co. (OGN) Securities Lawsuit Case Details  

Hauser v. Organon & Co., et al.  

Case No.: 2-25-cv-05322 

U.S. District Court, District of New Jersey 

Filed on May 23, 2025 

Organon & Co. (OGN) Securities Company Profile  

Organon is a global pharmaceutical company.  It's focused on women’s health, biosimilars, and legacy therapies.  It operates six manufacturing facilities internationally. In late 2024, Organon acquired Dermavant, which produces a dermatology drug called VTAMA.   

Class Period:  

The class period for the Organon & Co. (OGN) securities class action lawsuit was October 31, 2024 through April 30, 2025, inclusive.

Investors who purchased Organon securities during the Class Period might be eligible to join the Organon & Co securities class action lawsuit. 

Allegations in the Organon & Co.  (OGN) Securities Lawsuit

The Complaint alleges Organon misled investors about its financial priorities.  Plaintiffs claim the Company emphasized the importance of maintaining its quarterly dividend, while at the same time internal financial documents suggested another story altogether.  

On October 31, 2024, Organon released its Q3 earnings report and held the corresponding earnings call. During that call, CEO Kevin Ali highlighted the strategic rationale behind the Company's acquisition of Demavant.  Ali called the VTAMA asset “solidly accretive” and projecting “healthy margins” and long-term growth. CFO Matthew Walsh acknowledged a temporary increase in net leverage from the $340 million deal but assured investors that Organon was still positioned to deliver roughly $1 billion in free cash flow. Management made no indication that the dividend was in jeopardy. 

The lawsuit contends that these statements were misleading. Internally, Organon was already facing mounting debt obligations tied to the Dermavant acquisition.  In fact, the Company required cash redistribution and fast. Plaintiffs say investors were led to believe the dividend was secure, when in reality, management was preparing to shift capital toward accelerated deleveraging and the dividend funds were going to be used for Organon's debt reduction strategy. 

The Truth Emerges 

On May 1, 2025, Organon revealed that it would reduce its quarterly dividend by 70%, from $0.28 to $0.08 per share. The announcement, made in the company’s Q1 2025 earnings release and confirmed during the investor call, marked a sharp departure from months of guidance. 

Ali stated that the company had “reset our capital allocation priorities,” explaining that investor sentiment around leverage had prompted a shift toward debt reduction. Walsh added that the cut would allow Organon to reallocate approximately $200 million in annual dividend payments toward balance sheet management. 

The sudden reversal sparked skepticism from analysts. During the call’s Q&A segment, Evercore ISI pressed management on the timing, noting that just one quarter earlier, the dividend had been positioned as untouchable. While Ali cited macroeconomic challenges and changing investor expectations, he did not address why those same concerns hadn’t been communicated sooner. 

Market Reaction 

Following the May 1, 2025 announcement, Organon's stock price fell 27% in a single trading day—from $12.93 to $9.45 per share. Analysts at Evercore ISI and CFRA issued negative commentary and price target revisions, citing inconsistent capital allocation messaging and the sudden reversal on dividend policy. 

Next Steps  

• Submissions for lead plaintiff are due July 23, 2025 

• The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.    

• The Court will then consider motion for class certification.     

• The Court will later consider a Motion to Dismiss.     

To learn if you are eligible for recovery under the Organon securities class action lawsuit, visit the case submission page here. 

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.